A Randomized, Open-label, Phase 3 Study of MK-2870 vs. Platinum Doublets in Participants With EGFR-mutated, Advanced Nonsquamous Non-small Cell Lung Cancer (NSCLC) Who Have Progressed on Prior EGFR Tyrosine Kinase Inhibitors

Summary

The purpose of this study is to evaluate sacituzumab tirumotecan versus pemetrexed in combination with carboplatin for the treatment of epidermal growth factor receptor (EGFR)-mutated advanced non-squamous non-small cell lung cancer (NSCLC). Participants in this study have NSCLC that has continued to progress on prior treatment with EGFR tyrosine kinase inhibitors (TKIs). The primary hypotheses of this study is that sacituzumab tirumotecan is better than platinum-based doublet chemotherapy (pemetrexed and carboplatin) in regard to overall survival (OS).

Description

Eligibility

Age range

18+ years

Sex

All

Healthy volunteers

No

Interventions

• Biological
  Sacituzumab tirumotecan

  4 mg/kg via IV infusion

• Drug
  Pemetrexed

  500 mg/m\^2 via IV infusion

• Drug
  Carboplatin

  AUC 5 mg/mL\*min via IV infusion

• Drug
  H1 Receptor Antagonist

  Administered as rescue medication per approved product label

• Drug
  H2 Receptor Antagonist

  Administered as rescue medication per approved product label

• Drug
  Acetaminophen (or equivalent)

  Administered as rescue medication per approved product label

• Drug
  Dexamethasone (or equivalent)

Locations (156)